Unraveling a Rare Complication - Pembrolizumab-Induced Scleroderma: The Index Case in a Breast Cancer Patient

Pembrolizumab is a Programmed Cell Death protein-1 (PD-1) inhibitor which leads to increased T-cell activity which in turn increases anti-tumor immune response. Although immune-related Adverse Events (irAEs) are well-known complications to ICI therapy, limited evidence is available in the current literature regarding the incidence of scleroderma. We report a case of pembrolizumab-induced limited cutaneous scleroderma in a 37-year-old triple negative breast cancer patient.